Friday, 16 October 2026European Markets

PAYTON PLANAR Stock Went Up By Over 17% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of PAYTON PLANAR (BEL 20: PAY.BR) rose by a staggering 17.07% in 5 sessions from €8.2 to €9.60 at 23:22 EST on Wednesday, after four successive sessions in a row of gains. BEL 20 is sliding 1.29% to €3,536.79, after two successive sessions in a row of losses.

PAYTON PLANAR's last close was €9.65, 7.21% under its 52-week high of €10.40.

About PAYTON PLANAR

Payton Planar Magnetics Ltd., together with its subsidiaries, engages in development, manufacture, and marketing of planar and conventional transformers worldwide. It provides various planar transformers; inductors, including common mode chocks; and off the shelf SMT planar transformers. The company also supplies planar magnetic components. It serves telecom/datacenter, automotive companies, and industrial companies. The company was incorporated in 1992 and is based in Ness-Ziona, Israel. Payton Planar Magnetics Ltd. is a subsidiary of Payton Industries Ltd.

Earnings Per Share

As for profitability, PAYTON PLANAR has a trailing twelve months EPS of €0.84.

PE Ratio

PAYTON PLANAR has a trailing twelve months price to earnings ratio of 11.43. Meaning, the purchaser of the share is investing €11.43 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.81%.

Volume

Today's last reported volume for PAYTON PLANAR is 625 which is 74.37% below its average volume of 2263.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 61.54M for the twelve trailing months.

Moving Average

PAYTON PLANAR's worth is above its 50-day moving average of €8.76 and higher than its 200-day moving average of €9.31.

Yearly Top and Bottom Value

PAYTON PLANAR's stock is valued at €9.60 at 23:22 EST, under its 52-week high of €10.40 and way higher than its 52-week low of €7.50.

More news about PAYTON PLANAR (PAY.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com